Machavert’s Annual General Meeting

Machavert’s Shareholders Annual General Meeting took place on June 27th in Prague, Czech Republic. Machavert’s management shared an exciting progress update on the advancement of the formulation of our leading drug candidate MP1000 and the possibility to employ MP1000 as a delivery vehicle that can deliver other therapeutic payloads to tumors. Indeed, this opens up an entire new space of applicability of MP1000 in a whole range of therapeutic areas. Further, we informed the shareholders that the fundraising round of the tranche 2 of the Round A is nearing its closing at approximately $2.3 million. Lastly, we have completed restructuring of the company so as to position us better toward sought strategic partnership and we have discussed a strategy toward achieving this goal in the near future.